All In Biotech

Drug Trial Radar · NCT04181827

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 419 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

419

Actual

Start

Jun 12, 2020

Primary completion

May 1, 2024

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

Conditions

  • Multiple Myeloma

Interventions

  • Cilta-celDrug

    Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).

  • PomalidomideDrug

    Pomalidomide 4 mg will be administered orally.

  • BortezomibDrug

    Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).

  • DexamethasoneDrug

    Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.

  • DaratumumabDrug

    Daratumumab 1800 mg will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)

Locations

88 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Cancer Center-Scottsdale

    Phoenix, Arizona

  • Stanford University Medical Center

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • University Of Miami Leonard M Mille School Of Medicine SCCC

    Miami, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas

    Westwood, Kansas

  • University Of Maryland Medical Center

    Baltimore, Maryland

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University

    Columbus, Ohio

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Wisconsin Institutes for Medical Research

    Madison, Wisconsin

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Alfred Health

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Universitair Ziekenhuis - Antwerpen

    Antwerp, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • CHRU de Lille Hopital Claude Huriez

    Lille, France

  • Hospices Civils de Lyon HCL

    Lyon, France

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, France

  • C.H.U. Hotel Dieu - France

    Nantes, France

  • Hopital Saint Louis

    Paris, France

  • CHU De Poitiers

    Poitiers, France

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, France

  • Universitaetsklinikum Koeln

    Cologne, Germany

  • Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden

    Dresden, Germany

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.